DVLT Faces Fraud Investigation Amid Heavy Dilution and Unproven Tokenization Revenue

What happened

The Schall Law Firm announced a fraud investigation into Datavault AI Inc. (DVLT), inviting investors who suffered losses to join. This comes as DVLT's latest filings reveal a company burning $8.7M in operating cash per quarter with only $2.2M cash on hand, relying heavily on equity dilution—over 36 million shares sold via ATM in Q1 alone. The promised tokenization revenue, touted as nearly $100M in fees for 2026, has yet to appear in reported financials; Q1 revenue was just $3.4M with a 3% gross margin. Meanwhile, structured financings like the Scilex deal impose a stepped revenue share that caps upside for common shareholders before any real revenue scales. The investigation adds legal and regulatory overhang to a stock already pricing in execution risk, with the market cap at $115M despite a net loss of $53M last quarter.

Implication

The fraud investigation is a material negative for DVLT, adding legal costs and potential liability that the cash-strapped company can ill afford. Given the existing POTENTIAL SELL rating, this news reinforces the bear case: the tokenization narrative is unsupported by GAAP revenue, and management's reliance on dilutive financing is now paired with regulatory scrutiny. Investors should expect increased volatility and potential for further price declines if the investigation uncovers misrepresentations. The stock's attractive entry point of $0.28 noted in the report now looks more like a baseline, not a floor. Any position should be reduced or avoided until clarity emerges on both the investigation and meaningful tokenization revenue conversion.

Thesis delta

The fraud investigation introduces a new layer of legal and regulatory risk that was not fully priced in the original sell thesis. This shifts the re-assessment window forward, as the investigation could accelerate funding needs and damage credibility with partners and investors. The call to trim above $0.65 now seems optimistic; the priority is avoiding the stock entirely until the investigation's scope and financial impact are known.